SARS-CoV-2 VACCINES AND USES THEREOF

Patent metadata

Field	Value
Publication number	US-2023398208-A1
Application number	US-202318331879-A
Country	US
Kind code	A1
Filing date	Jun 8, 2023
Priority date	Jun 8, 2022
Publication date	Dec 14, 2023
Grant date	—

Abstract

SARS-CoV-2 vaccines are described herein. The SARS-CoV-2 vaccine antigens can be presented on a circular tandem repeat protein (cTRP) scaffold as trimers or tetramers. The vaccines can be used to treat and/or reduce the risk of SARS-CoV-2 infection and to treat and/or reduce the risk of side effects associated with SARS-CoV-2 infection, such as SARS-CoV-2-related symptoms, syndromes, and complications.

First claim

1 . A SARS-CoV-2 vaccine comprising the sequence as set forth in SEQ ID NO: 4 or 9 or a sequence having at least 98% sequence identity to the sequence as set forth in SEQ ID NO: 4 or 9.

2 . The SARS-CoV-2 vaccine of claim 1 , having 3 copies of SEQ ID NO: 4 or 3 copies of sequences having at least 98% sequence identity to the sequence as set forth in SEQ ID NO: 4, wherein the 3 copies self-assemble to result in trimeric presentation of the sequence as set forth in SEQ ID NO: 1 or a sequence having at least 98% sequence identity to the sequence as set forth in SEQ ID NO: 1.

3 . The SARS-CoV-2 vaccine of claim 1 , having 4 copies of SEQ ID NO: 9 or 4 copies of sequences having at least 98% sequence identity to the sequence as set forth in SEQ ID NO: 9, wherein the 4 copies self-assemble to result in tetrameric presentation of the sequence as set forth in SEQ ID NO: 5 or a sequence having at least 98% sequence identity to the sequence as set forth in SEQ ID NO: 5.

4 . The SARS-CoV-2 vaccine of claim 1 , comprising the sequence as set forth in SEQ ID NO: 3 or 8 or a sequence having at least 98% sequence identity to the sequence as set forth in SEQ ID NO: 3 or 8.

5 . The SARS-CoV-2 vaccine of claim 1 , the sequence as set forth in SEQ ID NO: 2 or 7 or a sequence having at least 98% sequence identity to the sequence as set forth in SEQ ID NO: 2 or 7.

6 - 40 . (canceled)

41 . A composition formulated for administration to a subject including a SARS-CoV-2 vaccine of claim 1 .

42 . The composition of claim 41 , further comprising an adjuvant.

43 . The composition of claim 42 , wherein the adjuvant comprises alum, a squalene-based adjuvant, a STING agonist, or a liposome-based adjuvant.

44 . The composition of claim 41 , further comprising anti-infective agent.

45 . The composition of claim 44 , wherein the anti-infective agent comprises a NS5B inhibitor or a protease inhibitor.

46 . The composition of claim 44 , wherein the anti-infective agent comprises remdesivir, lopinavir, ritonavir, favipiravir, fmgolimod, methylprednisolone, bevacizumab, tocilizumab, umifenovir, losartan, the monoclonal antibody combination of REGN3048 and REGN3051, ribavirin, AT-527 or AT-511.

47 . The composition of claim 41 , wherein the composition further comprises a second vaccine comprising mRNA-1273, AZD-1222, BNT162, Sputnik V, CoronaVac, NVX-CoV 2372, SCB-2019, ZyCoV-D, BBIBP-CorV, EpiVacCorona, Convidicea, Covid-19 Vaccine, JNJ-78436735, ZF2001, CVnCoV, INO-4800, VIR-7831, Covid-19 adenovirus bases vaccine, UB-612, or CoVaxin.

48 - 63 . (canceled)

64 . A nucleotide sequence encoding a SARS-CoV-2 vaccine of claim 1 .

65 . The nucleotide sequence of claim 64 , wherein the nucleotide sequence comprises DNA.

66 . The nucleotide sequence of claim 64 , wherein the nucleotide sequence comprises RNA.

67 . The nucleotide sequence of claim 64 , wherein the nucleotide sequence comprises messenger RNA (mRNA).

Assignees

• Fred Hutchinson Cancer Center

Inventors

• Price Jason
• Olson James
• Correnti Colin E
• Stoddard Barry L

Classifications

• A61K39/215 Primary

  Coronaviridae, e.g. avian infectious bronchitis virus · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title

• A61K2039/55555

  Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title